Clinical Trials

Investigating innovative treatments across a range of B-cell malignancies and solid tumors

Nurix is conducting three Phase 1 clinical trials across its protein modulation portfolio: two drug candidates from its protein degradation portfolio are under investigation for the treatment of relapsed/refractory B-cell malignancies, and one drug candidate from its protein elevation portfolio is under investigation for immuno-oncology indications including a range of solid tumor types and lymphoma.

NX-1607 Clinical Trial Contact Form

Please provide the following information.

By clicking Submit you are agreeing to the Nurix Privacy notice.